Equities analysts expect Inspire Medical Systems (NASDAQ:INSP) to post sales of $14.00 million for the current quarter, according to Zacks. Three analysts have issued estimates for Inspire Medical Systems’ earnings, with the lowest sales estimate coming in at $13.90 million and the highest estimate coming in at $14.10 million. The company is expected to issue its next quarterly earnings results on Tuesday, February 5th.
According to Zacks, analysts expect that Inspire Medical Systems will report full-year sales of $48.00 million for the current year, with estimates ranging from $47.90 million to $48.10 million. For the next fiscal year, analysts forecast that the firm will post sales of $63.33 million, with estimates ranging from $61.20 million to $64.50 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Inspire Medical Systems.
Inspire Medical Systems (NASDAQ:INSP) last announced its quarterly earnings results on Tuesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.13. The business had revenue of $13.10 million during the quarter, compared to analysts’ expectations of $12.86 million. During the same period last year, the company earned ($3.42) EPS. The firm’s revenue for the quarter was up 79.9% on a year-over-year basis.
In related news, CEO Timothy P. Herbert sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $39.89, for a total transaction of $598,350.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Randy Ban sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 20th. The shares were sold at an average price of $40.37, for a total transaction of $403,700.00. The disclosure for this sale can be found here.
Several institutional investors and hedge funds have recently made changes to their positions in INSP. MetLife Investment Advisors LLC purchased a new position in shares of Inspire Medical Systems during the third quarter valued at approximately $199,000. Valeo Financial Advisors LLC acquired a new position in Inspire Medical Systems during the second quarter worth approximately $229,000. Rhumbline Advisers acquired a new position in Inspire Medical Systems during the second quarter worth approximately $243,000. Bank of America Corp DE acquired a new position in Inspire Medical Systems during the second quarter worth approximately $306,000. Finally, Dupont Capital Management Corp acquired a new position in Inspire Medical Systems during the third quarter worth approximately $314,000.
Shares of NASDAQ INSP opened at $45.94 on Monday. Inspire Medical Systems has a 12-month low of $22.50 and a 12-month high of $57.87.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
See Also: Rule of 72
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.